789 related articles for article (PubMed ID: 21672045)
1. Emerging moulds: epidemiological trends and antifungal resistance.
Miceli MH; Lee SA
Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045
[TBL] [Abstract][Full Text] [Related]
2. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.
Cornely OA
Infection; 2008 Aug; 36(4):296-313. PubMed ID: 18642109
[TBL] [Abstract][Full Text] [Related]
3. Changing epidemiology of systemic fungal infections.
Richardson M; Lass-Flörl C
Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
[TBL] [Abstract][Full Text] [Related]
4. Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification.
Araujo R; Oliveira M; Amorim A; Sampaio-Maia B
Eur J Clin Microbiol Infect Dis; 2015 Jul; 34(7):1289-301. PubMed ID: 25894985
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and challenges in the treatment of invasive fungal infections.
Shao PL; Huang LM; Hsueh PR
Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
[TBL] [Abstract][Full Text] [Related]
6. Emerging systemic fungal infections.
Galimberti R; Torre AC; Baztán MC; Rodriguez-Chiappetta F
Clin Dermatol; 2012; 30(6):633-50. PubMed ID: 23068151
[TBL] [Abstract][Full Text] [Related]
7. Meeting the challenge of invasive fungal infections: part 1.
Maertens J; Lyon S
Future Microbiol; 2013 Sep; 8(9):1063-5. PubMed ID: 24020734
[TBL] [Abstract][Full Text] [Related]
8. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections.
Lewis RE
Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618
[TBL] [Abstract][Full Text] [Related]
9. Overview of invasive fungal infections.
Tuite NL; Lacey K
Methods Mol Biol; 2013; 968():1-23. PubMed ID: 23296882
[TBL] [Abstract][Full Text] [Related]
10. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
11. Emerging fungal resistance.
Baddley JW; Moser SA
Clin Lab Med; 2004 Sep; 24(3):721-35, vii. PubMed ID: 15325062
[TBL] [Abstract][Full Text] [Related]
12. New developments in invasive fungal disease.
Groll AH; Lumb J
Future Microbiol; 2012 Feb; 7(2):179-84. PubMed ID: 22324986
[TBL] [Abstract][Full Text] [Related]
13. Current status of antifungal resistance and its impact on clinical practice.
Alcazar-Fuoli L; Mellado E
Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
[TBL] [Abstract][Full Text] [Related]
14. Invasive fungal infection--laboratory diagnosis and antifungal treatment.
Shao PL; Huang LM; Hsueh PR
J Microbiol Immunol Infect; 2006 Jun; 39(3):178-88. PubMed ID: 16783447
[TBL] [Abstract][Full Text] [Related]
15. Strategies to manage antifungal drug resistance.
Tseng HK; Perfect JR
Expert Opin Pharmacother; 2011 Feb; 12(2):241-56. PubMed ID: 21226635
[TBL] [Abstract][Full Text] [Related]
16. Newer antifungal therapy for emerging fungal pathogens.
Steinbach WJ; Perfect JR
Int J Infect Dis; 2003 Mar; 7(1):5-20. PubMed ID: 12718805
[TBL] [Abstract][Full Text] [Related]
17. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections.
Horn DL; Fishman JA; Steinbach WJ; Anaissie EJ; Marr KA; Olyaei AJ; Pfaller MA; Weiss MA; Webster KM; Neofytos D
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):407-14. PubMed ID: 17888614
[TBL] [Abstract][Full Text] [Related]
18. Emerging infections caused by non-Aspergillus filamentous fungi.
Douglas AP; Chen SC; Slavin MA
Clin Microbiol Infect; 2016 Aug; 22(8):670-80. PubMed ID: 26812445
[TBL] [Abstract][Full Text] [Related]
19. Common and emerging fungal pulmonary infections.
Hsu LY; Ng ES; Koh LP
Infect Dis Clin North Am; 2010 Sep; 24(3):557-77. PubMed ID: 20674792
[TBL] [Abstract][Full Text] [Related]
20. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
